A total of 683 patients with advanced (stage III) or metastatic (stage IV) melanoma and EHR documented evidence of BRAF mutated lesions treated with 1L immunotherapy anti‐CTLA4/anti‐PD1/combo (n = 266), or targeted BRAF/combo (n = 417), who did not have brain metastases at 1L initiation, were identified and included in our primary study. The gene discussed is CTLA4; the disease is melanoma.